Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 15 studies | 26% ± 9% | |
fibroblast | 9 studies | 20% ± 7% | |
endothelial cell of lymphatic vessel | 7 studies | 24% ± 6% | |
adipocyte | 6 studies | 26% ± 5% | |
type I pneumocyte | 5 studies | 25% ± 5% | |
epithelial cell | 4 studies | 27% ± 11% | |
cardiac muscle cell | 4 studies | 20% ± 1% | |
monocyte | 4 studies | 17% ± 1% | |
macrophage | 4 studies | 22% ± 3% | |
smooth muscle cell | 3 studies | 19% ± 2% | |
astrocyte | 3 studies | 26% ± 3% |
Insufficient scRNA-seq data for expression of LATS2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3223.92 | 1444 / 1445 | 99% | 24.66 | 182 / 183 |
skin | 100% | 3005.50 | 1804 / 1809 | 99% | 25.16 | 469 / 472 |
prostate | 100% | 2386.36 | 244 / 245 | 99% | 19.87 | 496 / 502 |
lung | 100% | 3597.32 | 578 / 578 | 97% | 15.59 | 1126 / 1155 |
kidney | 99% | 1584.55 | 88 / 89 | 97% | 23.81 | 876 / 901 |
breast | 100% | 3645.50 | 459 / 459 | 96% | 16.06 | 1070 / 1118 |
uterus | 100% | 3305.24 | 170 / 170 | 92% | 12.55 | 421 / 459 |
ovary | 100% | 2986.27 | 180 / 180 | 92% | 11.22 | 394 / 430 |
thymus | 100% | 3725.47 | 653 / 653 | 91% | 22.03 | 552 / 605 |
intestine | 96% | 2735.48 | 923 / 966 | 94% | 13.74 | 495 / 527 |
bladder | 100% | 3401.05 | 21 / 21 | 89% | 11.08 | 450 / 504 |
stomach | 88% | 1833.53 | 317 / 359 | 95% | 17.29 | 271 / 286 |
adrenal gland | 100% | 2437.84 | 258 / 258 | 67% | 9.03 | 153 / 230 |
pancreas | 67% | 623.00 | 221 / 328 | 96% | 21.18 | 171 / 178 |
liver | 79% | 748.23 | 179 / 226 | 76% | 8.39 | 309 / 406 |
adipose | 100% | 4753.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5504.48 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 24.50 | 80 / 80 |
muscle | 100% | 2659.54 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.96 | 1 / 1 |
spleen | 99% | 1616.12 | 239 / 241 | 0% | 0 | 0 / 0 |
heart | 98% | 2072.31 | 846 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 84% | 9.98 | 38 / 45 |
brain | 23% | 201.21 | 616 / 2642 | 52% | 5.37 | 364 / 705 |
lymph node | 0% | 0 | 0 / 0 | 59% | 5.49 | 17 / 29 |
peripheral blood | 58% | 643.73 | 536 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046620 | Biological process | regulation of organ growth |
GO_0017015 | Biological process | regulation of transforming growth factor beta receptor signaling pathway |
GO_0030216 | Biological process | keratinocyte differentiation |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0035329 | Biological process | hippo signaling |
GO_0001827 | Biological process | inner cell mass cell fate commitment |
GO_0051301 | Biological process | cell division |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0009755 | Biological process | hormone-mediated signaling pathway |
GO_1900181 | Biological process | negative regulation of protein localization to nucleus |
GO_0008104 | Biological process | protein localization |
GO_0006468 | Biological process | protein phosphorylation |
GO_0045736 | Biological process | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0001828 | Biological process | inner cell mass cellular morphogenesis |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0034451 | Cellular component | centriolar satellite |
GO_0000922 | Cellular component | spindle pole |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LATS2 |
Protein name | Serine/threonine-protein kinase LATS2 (EC 2.7.11.1) (Kinase phosphorylated during mitosis protein) (Large tumor suppressor homolog 2) (Serine/threonine-protein kinase kpm) (Warts-like kinase) |
Synonyms | KPM |
Description | FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ. . |
Accessions | ENST00000382592.5 Q9NRM7 |